Zinzino group revenue increased 56% in Q2, compared with the previous year.
GOTHENBURG, Sweden, July 3, 2025 /PRNewswire/ -- The revenue in June for Zinzino's sales...
MUMBAI, India, July 3, 2025 /PRNewswire/ -- Bound, India's leading creative education platform, announces the next edition of The Bound Publishing Course, a first-of-its-kind,...
Bang & Olufsen ended the year with 4% revenue growth in Q4 and a 1% decline in local currencies for the full year, bringing total revenue to DKK 2.6bn. The gross margin continued to increase, reaching a record-high 55.8% in Q4, and 55.0% at year end. For the full year, the EBIT margin before special items was 1.0%, and free cash flow amounted to DKK 16m. Overall, the results were in line with plans and aligned with the outlook for the year.
Bang & Olufsen afsluttede året med en omsætningsvækst på 4% i 4. kvartal og et fald på 1% målt i lokal valuta for hele året, hvilket bragte den samlede koncernomsætning op på DKK 2,6 mia. Bruttomarginen fortsatte med at stige til et rekordhøjt niveau på 55,8% i 4. kvartal og 55,0% for året. For hele året udgjorde EBIT-marginen før særlige poster 1,0%, og det frie cash flow udgjorde DKK 16 mio. Overordnet set var resultatet i tråd med virksomhedens planer og på niveau med forventningerne for året.
New York City, NY, July 03, 2025 (GLOBE NEWSWIRE) -- In 2025, Nixol, a plant-based dietary supplement, made its debut in the United Kingdom and Ireland, marking a significant entry into the wellness supplement market. Designed to support healthy weight management, boost metabolism, and curb cravings, Nixol has positioned itself as a natural, vegan-friendly alternative to traditional weight loss solutions. Unlike products that rely on synthetic stimulants or restrictive diets, Nixol leverages a blend of carefully selected, science-backed ingredients to promote sustainable fat reduction and overall well-being. This article provides an in-depth exploration of Nixol’s launch, its formulation, claims, scientific backing, customer feedback, and the broader context of its market entry, while critically examining its potential effectiveness and limitations. Visit Official Website
Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs...
Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs...
- Carro's 'No Drama' award-winning ad series parodies drama cliches to highlight its trustworthy, reliable, and transparent practices, with the latest ad paying homage...
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against AppLovin Corporation (NASDAQ:APP) on behalf of long-term stockholders following a class action complaint that was filed against AppLovin on March 5, 2025 with a Class Period from May 10, 2023 to March 26, 2025.. Our investigation concerns whether the board of directors of AppLovin have breached their fiduciary duties to the company.
MONTRÉAL, July 2, 2025 /CNW/ - Geekco Technologies Corporation (the "Corporation" or "Geekco") (TSXV: GKO) is pleased to announce that, in accordance with the terms...